Position in NVS
as of Jun 30, 2026
· filed Jul 7, 2026
Position Value
$236,490
+$24,932 QoQ
Shares Held
1,509
+9.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#1,241
of 1,603 holders
Holding Since
Mar 2020
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Balefire, LLC holds $12,645,380 across 10 Drug Manufacturers - General names. NVS ranks #10 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
4,262 | $5,111,971 | |
| 2 | JNJ |
Johnson & Johnson
|
5,701 | $1,447,882 | |
| 3 | MRK |
Merck & Co., Inc.
|
10,039 | $1,290,011 | |
| 4 | AMGN |
Amgen Inc
|
3,296 | $1,193,547 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
18,299 | $1,054,388 | |
| 6 | ABBV |
AbbVie Inc.
|
3,997 | $1,005,805 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
5,982 | $755,765 | |
| 8 | AZN |
Astrazeneca PLC
|
1,645 | $311,924 |
All Filings in NVS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $236,490 | 1,509 | Shares | Sole | 2026-07-07 | |
| 2026-03-31 | $211,558 | 1,385 | Shares | Sole | 2026-05-07 | |
| 2024-06-30 | $6,281 | 59 | Shares | Sole | 2024-08-01 | |
| 2024-03-31 | $5,707 | 59 | Shares | Sole | 2024-05-10 | |
| 2023-12-31 | $5,957 | 59 | Shares | Sole | 2024-02-07 | |
| 2020-03-31 | $206,867 | 2,509 | Shares | Sole | 2020-05-15 | |
| No filing history on record for this holder in this stock. | ||||||